Weight Loss Injections Show Promise for Children Aged 6-11 in New Study
Translated & summarized from Ice by baba
A new study indicates that the weight loss drug Wegovy may effectively reduce BMI in children aged six to 11 with obesity. The trial, which included 16 Israeli children, showed significant results after 68 weeks, though long-term effects require further study. Wegovy is not yet approved for this age group in Israel, where it is currently available for those 12 and older.
The story in 5 lines · by baba
- A new study suggests Wegovy injections can significantly reduce BMI in children aged 6-11 with obesity.
- Nearly 79% of child participants in the study achieved a substantial BMI reduction with Wegovy.
- Sixteen Israeli children participated in the international trial, which was conducted at several Israeli hospitals.
- Wegovy is not yet approved for children under 12 in Israel, where it's available for those 12 and older.
- Long-term effects of Wegovy on children's growth and development require further investigation.
A new study published in the New England Journal of Medicine suggests that weight loss injections, specifically Wegovy, may be effective for children aged six to 11 suffering from obesity. The research, part of the STEP Young trial by Novo Nordisk, involved 167 children, with over 85% classified as severely obese. Participants were divided into a Wegovy group and a placebo group, with both receiving nutritional and exercise guidance.
After 68 weeks, nearly 79% of children in the Wegovy group achieved a significant reduction in Body Mass Index (BMI), with an average decrease of 17.4%. In contrast, the placebo group saw a 2.2% increase in BMI. Approximately 40% of the children receiving Wegovy no longer met the medical definition of obesity.
Sixteen children from Israel participated in the trial, which was conducted at Israeli medical centers including Rambam, Schneider, and Shamir-Assaf Harofeh. While these results are encouraging, researchers emphasize that long-term data on the drug's effects, particularly on growth and development, is still needed. Common side effects like nausea, vomiting, and diarrhea were reported, but no unexpected safety issues were identified.
Wegovy is currently approved in Israel for individuals aged 12 and above, and is sometimes covered by the national health basket for teenagers. Its use for younger children is not yet approved, and no timeline for potential expansion has been announced. The cost of these injections in Israel can range from hundreds to over a thousand shekels per month, depending on the specific drug, dosage, and insurance coverage.
Mentioned